---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-086529"
form_type: "8-K"
ticker: "LQDA"
cik: "0001819576"
company_name: "Liquidia Corp"
filed_at: "2024-08-07T23:59:59+00:00"
generated_at: "2026-05-31T11:52:08.636438+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Liquidia Q2 net loss $27.9M; court rulings clear legal path for YUTREPIA approval

## Summary
- Q2 net loss $27.9M ($0.37/share) vs $23.5M ($0.36/share) in Q2 2023.
- Revenue from Sandoz promotion $3.7M, down from $4.8M due to lower sales volumes.
- Cash and equivalents $133.1M at June 30, 2024, up from $83.7M at Dec 31, 2023.
- Court denied UTHR's preliminary injunction on YUTREPIA patent '327 on May 31; D.C. court also denied TRO/PI against FDA.
- R&D expense fell 47% to $9.4M (no prior-year license fee); G&A rose 116% to $20.0M on sales force and legal costs.

## SEC filing metadata
- accession: 0001104659-24-086529
- form_type: 8-K
- ticker: LQDA
- cik: 0001819576
- company_name: Liquidia Corp
- filed_at: 2024-08-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1819576/000110465924086529/0001104659-24-086529-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1819576/000110465924086529/tm2420885d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-086529
- JSON: https://secwatch.observer/filing/0001104659-24-086529.json
- Plain text: https://secwatch.observer/filing/0001104659-24-086529.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.